Technical Analysis for TLX - Telix Pharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Gapped Up | Strength | -3.31% | |
| MACD Bearish Signal Line Cross | Bearish | -3.56% | |
| Pocket Pivot | Bullish Swing Setup | -3.56% | |
| Outside Day | Range Expansion | -3.56% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.55% | |
| NR7 | Range Contraction | -2.55% | |
| Narrow Range Bar | Range Contraction | -2.55% | |
| Inside Day | Range Contraction | -2.55% | |
| Down 3 Days in a Row | Weakness | -2.55% |
| Alert | Time |
|---|---|
| Down 1 ATR | about 15 hours ago |
| Down 3% | about 15 hours ago |
| Fell Below 20 DMA | about 15 hours ago |
| Down 2% | about 16 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
Sector: Healthcare
Industry: Biotechnology
Keywords: Natural Sciences Medicine Pharmaceutical Radio Cancer Drugs Pharmaceuticals Biopharmaceutical Profile Therapeutic Product Therapeutic Products Radiation Brain Cancer Prostate Cancer Radiation Therapy Radiopharmaceuticals Glioblastoma Radioactivity Radiopharmaceutical
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Natural Sciences Medicine Pharmaceutical Radio Cancer Drugs Pharmaceuticals Biopharmaceutical Profile Therapeutic Product Therapeutic Products Radiation Brain Cancer Prostate Cancer Radiation Therapy Radiopharmaceuticals Glioblastoma Radioactivity Radiopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.99 |
| 52 Week Low | 9.06 |
| Average Volume | 1,053,747 |
| 200-Day Moving Average | 17.137 |
| 50-Day Moving Average | 21.227 |
| 20-Day Moving Average | 22.322 |
| 10-Day Moving Average | 22.955 |
| Average True Range | 0.753 |
| RSI (14) | 50.74 |
| ADX | 14.67 |
| +DI | 22.478 |
| -DI | 24.569 |
| Chandelier Exit (Long, 3 ATRs) | 21.731 |
| Chandelier Exit (Short, 3 ATRs) | 22.769 |
| Upper Bollinger Bands | 24.064 |
| Lower Bollinger Band | 20.579 |
| Percent B (%b) | 0.47 |
| BandWidth | 15.616 |
| MACD Line | 0.491 |
| MACD Signal Line | 0.580 |
| MACD Histogram | -0.089 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.985 | ||||
| Resistance 3 (R3) | 24.127 | 23.673 | 23.688 | ||
| Resistance 2 (R2) | 23.673 | 23.219 | 23.603 | 23.588 | |
| Resistance 1 (R1) | 22.937 | 22.938 | 22.710 | 22.795 | 23.489 |
| Pivot Point | 22.483 | 22.483 | 22.370 | 22.413 | 22.483 |
| Support 1 (S1) | 21.747 | 22.029 | 21.520 | 21.605 | 20.911 |
| Support 2 (S2) | 21.293 | 21.748 | 21.223 | 20.812 | |
| Support 3 (S3) | 20.557 | 21.293 | 20.713 | ||
| Support 4 (S4) | 20.415 |
